US Stock Insider Trading | Revelation disclosed 5 insider trading transactions on February 5

K-LinePoet · 2026-02-26T15:35:48+00:00

Revelation (REVB) disclosed recent insider trading on February 5, 2026, primarily involving the selling transactions of executive Zygmont Chester Stanley III. The company focuses on developing immunotherapies, with main products including REVTx-99 and REVTx-200, dedicated to preventing and treating respiratory viral infections.

K-LinePoet

2026-02-26 15:35:48

Abstract generation in progress

On February 5, 2026, Revelation (REVB) disclosed five insider trading transactions. Executive Zygmont Chester Stanley III sold 13,100 shares on February 4, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 5, 2026	Director	Chawla Lakhmir S, ROPER JESS	February 3, 2026	Sell	3,852	1.85	7,126.20
February 5, 2026	Director	CARVER JENNIFER	February 3, 2026	Sell	1,661	1.87	3,106.07
February 5, 2026	Executive	Zygmont Chester Stanley III	February 4, 2026	Sell	13,100	1.65	21,600
February 5, 2026	Director	Rolke James	February 3, 2026	Sell	8,521	1.86	15,800
January 12, 2026	Director	CARVER JENNIFER, Chawla Lakhmir S, ROPER JESS	January 8, 2026	Buy	125,900	0.90	113,300
January 12, 2026	Director	Rolke James	January 8, 2026	Buy	532,800	0.90	479,500
January 12, 2026	Executive	Zygmont Chester Stanley III	January 8, 2026	Buy	78,100	0.90	70,300
October 31, 2025	Director	Rolke James	October 29, 2025	Buy	390,600	1.28	500,000
October 31, 2025	Executive	Zygmont Chester Stanley III	October 29, 2025	Buy	390,600	1.28	500,000
October 31, 2025	Director	CARVER JENNIFER, Chawla Lakhmir S, ROPER JESS	October 29, 2025	Buy	46,900	1.28	60,000

[Company Profile]

Revelation Biosciences, Inc. is a Delaware corporation founded on November 20, 2019. The company is a clinical-stage life sciences firm focused on developing immunotherapies for disease prevention and treatment. Revelation has several candidates in development. REVTx-99 is the lead therapeutic candidate, an intranasal immunomodulator designed to prevent or treat infections caused by various respiratory viruses. REVTx-99 is also being developed for other indications such as allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjuvant intended to be used with injectable vaccines to achieve more comprehensive immunity. Revelation is also developing REVDx-501, a rapid home diagnostic tool for detecting any respiratory virus infection without specialized equipment.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.